CINCINNATI / May 20, 2024 / Business Wire / Stockholders of Chemed Corporation (NYSE:CHE) today elected a slate of 10 directors at the Company’s 2024 annual stockholders’ meeting.
Stockholders ratified the continuation of PricewaterhouseCoopers LLP as the Company’s independent accountants for 2024. Stockholders also approved Chemed’s executive compensation. In addition, stockholders voted against the stockholder proposal on ratification of termination pay.
Dividend Declared
Following the stockholders’ meeting, Chemed’s Board of Directors declared a quarterly cash dividend of 40 cents per share on the Company’s capital stock, payable on June 18, 2024, to stockholders of record as of May 30, 2024. This represents the 212th consecutive quarterly dividend paid to stockholders in Chemed’s 53 years as a public company.
Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care, and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.
Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.
Last Trade: | US$562.00 |
Daily Change: | 0.66 0.12 |
Daily Volume: | 94,246 |
Market Cap: | US$8.420B |
November 05, 2024 October 29, 2024 July 24, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load